ImmuONE Raises $600K to Accelerate Human-Relevant Inhalation Safety Innovations

ImmuONE is thrilled to announce a major funding milestone, having raised $600,000 to accelerate the development of our innovative respiratory research solutions. Specializing in human alveolar macrophage responses, epithelial cell culture platforms, and comprehensive testing services, ImmuONE leads the way in creating respiratory tissue models that closely mimic lung physiology to deliver relevant, reliable, and reproducible results. With this new injection of capital, we are set to expand our cutting-edge inhalation safety assessment services—including advanced testing for inhalation toxicology, irritation sensitization, alveolar clearance, and inflammation—while also advancing our work in developing sustainable, animal product-free cell models. Our strategic partnerships with industry leaders and academic institutions will play a pivotal role in guiding the next stage of our research and technology enhancements, ensuring that our products not only meet current safety assessment needs but also set new standards for human-relevant, mechanistic-driven evaluations. This investment further solidifies our commitment to pioneering safe and effective testing solutions, empowering researchers and businesses alike to make informed decisions in respiratory health and toxicology. We are excited about the potential impact of this funding on our research capabilities and on the broader scientific community, and look forward to exploring new opportunities to drive sustainable innovation in safety assessment technologies. To learn more about our products, services, and the exciting developments ahead, please visit our website at www.immuone.com and follow our updates on Twitter @ImmuONE.